|
1
|
Kent WD, Hall SF, Isolato PA, Houlden RL,
George RL and Groome PA: Increased incidence of differentiated
thyroid carcinoma and detection of subclinical disease. CMAJ.
177:1357–1361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alvarado R, Sywak MS, Delbridge L and Sidu
SB: Central lymph node dissection as a secondary procedure for
papillary thyroid cancer: Is there added morbidity? Surgery.
145:514–518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee YS, Lim YS, Lee JC, Wang SG, Kim IJ
and Lee BJ: Clinical implication of the number of central lymph
node metastasis in papillary thyroid carcinoma: preliminary report.
World J Surg. 34:2558–2563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wan H, Zhang B, Liu S, et al: Preliminary
study of patterns of level IIb lymph node metastasis in papillary
thyroid carcinoma. Zhonghua Er Bai Yan Hou Tou Jing Wai Ke Za Zhi.
49:27–30. 2014.[(In Chinese)].
|
|
5
|
Eun YG, Lee YC and Kwon KH: Predictive
factors of contralateral paratracheal lymph node metastasis in
papillary thyroid cancer: prospective multicenter study.
Otolaryngol Head Neck Surg. 150:210–215. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cooper DS, Doherty GM, Haugen BR, et al:
American Thyroid Association Guidelines Taskforce: Management
guidelines for patients with thyroid nodules and differentiated
thyroid cancer. Thyroid. 16:109–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Frasoldati A, Toschi E, Zini M, et al:
Role of thyroglobulin measurement in fine-needle aspiration
biopsies of cervical lymph nodes in patients with differentiated
thyroid cancer. Thyroid. 9:105–111. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS
and Kim EK: Preoperative staging of papillary thyroid carcinoma:
comparison of ultrasound imaging and CT. AJR Am J Roentgenol.
193:871–878. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim MJ, Kim EK, Kim BM, et al:
Thyroglobulin measurement in fine-needle aspirate washouts: the
criteria for neck node dissection for patients with thyroid cancer.
Clin Endocrinol (Oxf). 70:145–151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pacini F, Fugazzola L, Lippi F, et al:
Detection of thyroglobulin in fine needle aspirates of nonthyroidal
neck masses: a clue to the diagnosis of metastatic differentiated
thyroid cancer. J Clin Endocrinol Metab. 74:1401–1404. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Z, Bai Y, Li P, Zhao J, Wang Y, Sun
L and Tang J: Relationship between activated STAT3 protein and
epithelial-mesenchymal transition in papillary thyroid carcinonma.
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 27:1265–1268.
2013.[(In Chinese)]. PubMed/NCBI
|
|
12
|
Slattery ML, John EM, Stern MC, et al:
Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2,
NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast
Cancer Health Disparities Study. Breast Cancer Res Treat.
140:587–601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jebreel A, England J, Bedford K, Murphy J,
Karsai L and Atkin S: Vascular endothelial growth factor (VEGF),
VEGF receptors expression and microvascular density in benign and
malignant thyroid diseases. Int J Exp Pathol. 88:271–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dralle H and Machens A: Surgical
approaches in thyroid cancer and lymph-node metastases. Best Pract
Res Clin Endocrinol Metab. 22:971–987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakorafas GH, Sampanis D and Safioleas M:
Cervical lymph node dissection in papillary thyroid cancer: current
trends, persisting controversies, and unclarified uncertainties.
Surg Oncol. 19:e57–e70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bournazou E and Bromberg J: Targeting the
tumor microenvironment: JAK-STAT3 signaling. JAKSTAT.
2:e238282013.PubMed/NCBI
|
|
17
|
Voskas D, Ling LS and Woodgett JR: Signals
controlling un-differentiated states in embryonic stem and cancer
cells: role of the phosphatidylinositol 3′ kinase pathway. J Cell
Physiol. 229:1312–1322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zouein FA, Duhé RJ and Booz GW: JAKs go
nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression
and cell growth. Growth Factors. 29:245–252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kamran MZ, Patil P and Gude RP: Role of
STAT3 in cancer metastasis and translational advances. Biomed Res
Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feng Y, Ke C, Tang Q, et al: Metformin
promotes autophagy and apoptosis in esophageal squamous cell
carcinoma by downregulating Stat3 signaling. Cell Death Dis.
5:e10882014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pandurangan AK and Esa NM: Signal
transducer and activator of transcription 3 - a promising target in
colitis-associated cancer. Asian Pac J Cancer Prev. 15:551–560.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Gill A, Atmore B, Johns A,
Delbridge L, Lai R and McMullen T: Upregulation of the signal
transducers and activators of transcription 3 (STAT3) pathway in
lymphatic metastases of papillary thyroid cancer. Int J Clin Exp
Pathol. 4:356–362. 2011.PubMed/NCBI
|
|
23
|
Kawakami Y, Yaguchi T, Sumimoto H, et al:
Improvement of cancer immunotherapy by combing molecular targeted
therapy. Front Oncol. 3:1362013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gu L, Talati P, Vogiatzi P, et al:
Pharmacological suppression of JAK1/2 by JAK1/2 inhibitor AZD1480
potently inhibits IL-6-induced experimental prostate cancer
metastases formation. Mol Cancer Ther. 13:1246–1258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Farren MR, Carlson LM, Netherby CS, et al:
Tumor-induced STAT3 signaling in myeloid cells impairs dendritic
cell generation by decreasing PKCβII abundance. Sci Signal.
7:ra162014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iwata-Kajihara T, Sumimoto H, Kawamura N,
et al: Enhanced cancer immunotherapy using STAT3-depleted dendritic
cells with high Th1-inducing ability and resistance to cancer
cell-derived inhibitory factors. J Immunol. 187:27–36. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Wang J, Wang X, et al: STAT3, a
poor survival predicator, is associated with lymph node metastasis
from breast cancer. J Breast Cancer. 16:40–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bednarek I, Sypniewski D, Gawlik N,
Galilejczyk A and Goraus K: The efficiency of silencing expression
of the gene coding STAT3 transcriptional factor and susceptibility
of bladder cancer cells to apoptosis. Contemp Oncol (Pozn).
16:316–321. 2012.PubMed/NCBI
|
|
29
|
Couto JP, Daly L, Almeida A, et al: STAT3
negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci USA.
109:E2361–E2370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dong L, Li Y, Cao J, et al: FGF2 regulates
melanocytes viability through the STAT3-transactivated PAX3
transcription. Cell Death Differ. 19:616–622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Coleman SJ, Chioni AM, Ghallab M, et al:
Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate
cells facilitates pancreatic cancer cell invasion. EMBO Mol Med.
6:467–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee HJ, Seo AN, Park SY, et al: Low
prognostic implication of fibroblast growth factor family
activation in triple-negative breast cancer subsets. Ann Surg
Oncol. 21:1561–1568. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meng QH, Xu E, Hildebrandt MA, et al:
Genetic variants in the fibroblast growth factor pathway as
potential markers of ovarian cancer risk, therapeutic response, and
clinical outcome. Clin Chem. 60:222–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang C, Huang R, Chang W, et al: The
expression and clinical significance of pSTAT3, VEGF and VEGF-C in
pancreatic adenocarcinoma. Neoplasma. 59:52–61. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu XM, Lo CY, Chan WF, Lam KY, Leung P and
Luk JM: Increased expression of vascular endothelial growth factor
C in papillary thyroid carcinoma correlates with cervical lymph
node metastases. Clin Cancer Res. 11:8063–8069. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karaca Z, Tanriverdi F, Unluhizarci K, et
al: VEGFR1 expression is related to lymph node metastasis and serum
VEGF may be a marker of progression in the follow-up of patients
with differentiated thyroid carcinoma. Eur J Endocrinol.
164:277–284. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hai-yun S, Deng-ting C and Shou-yi D:
Preoperative and postoperative serum VEGF-C levels and its clinical
significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 26:903–904.
2010.[(In Chinese)]. PubMed/NCBI
|
|
38
|
Emoto N, Onose H, Sugihara H, Minami S,
Shimizu K and Wakabayashi I: Fibroblast growth factor-2 free from
extracellular matrix is increased in papillary thyroid carcinomas
and Graves' thyroids. Thyroid. 8:491–497. 1998. View Article : Google Scholar : PubMed/NCBI
|
